{"id":389316,"date":"2022-12-27T00:00:00","date_gmt":"2022-12-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0016-2022-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-geographic-focus-china-squamous-cell-carcinoma-of\/"},"modified":"2026-03-31T10:35:30","modified_gmt":"2026-03-31T10:35:30","slug":"concon0016-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-geographic-focus-china-squamous-cell-carcinoma-of","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0016-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-geographic-focus-china-squamous-cell-carcinoma-of\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck &#8211; Geographic Focus: China &#8211; Squamous Cell Carcinoma of the Head and Neck &#8211; China In-Depth (China)"},"content":{"rendered":"<p>Squamous cell carcinoma of the head and neck (<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>)\u2014one of the most commonly diagnosed cancers in China\u2014has a dynamic drug development pipeline, including targeted and biomarker-driven therapies. The management of locally advanced <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> is often complex and requires a combination of therapies \/ procedures including surgery, radiotherapy, and chemotherapy. For nearly a decade, the <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr> inhibitor Erbitux (Eli Lilly \/ Merck KGaA) was the cornerstone therapy in the treatment algorithm of <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>, but the approval of Merck &#038; Co.\u2019s Keytruda for untreated recurrent or metastatic <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> marked a turning point in the treatment landscape of the disease. We expect that many novel therapies will launch for the treatment of both metastatic and early-stage <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> during the 2021-2031 forecast period, which will lead to significant growth of this market in China. Additionally, following the recent reforms in China\u2019s regulatory and reimbursement landscape, manufacturers\u2014both domestic and multinational\u2014will be increasingly incentivized to enter the growing <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> market.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is China\u2019s drug-treatable <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> therapy market, and why? What are interviewed experts\u2019 insights into current treatments?<\/li>\n<li>What are the market access considerations for key therapies in the <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> pipeline in China? What sales could these agents secure in <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>? What are interviewed experts\u2019 opinions of key emerging therapies?<\/li>\n<li>What are the key drivers and constraints in China\u2019s <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>China In-Depth<\/em> offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&#038;R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n<p><strong>Release date<\/strong><\/p>\n<p>September 2022<\/p>\n<p><strong>Geography<\/strong><\/p>\n<p>China<\/p>\n<p><strong>Primary research <\/strong><\/p>\n<p>Country-specific qualitative and quantitative insights based on 5 thought-leader interviews and surveys of 75 medical oncologists.<\/p>\n<p><strong>Epidemiology <\/strong><\/p>\n<p>Diagnosed incidence of <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.<\/p>\n<p><strong>FORECAST<\/strong><\/p>\n<p>10-year, annualized, drug-level sales and patient share of key <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p><strong>E<\/strong><strong>MERGING<\/strong><strong> THERAPIES<\/strong><\/p>\n<p>Phase III\/preregistered: 10+ drugs; Phase II: 20+ drugs; coverage of select Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-389316","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389316\/revisions"}],"predecessor-version":[{"id":576148,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389316\/revisions\/576148"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}